|
| 31806689 | LJ000328, a novel ALK2/3 kinase inhibitor, represses hepcidin and significantly improves the phenotype of IRIDA. | Haematologica | 2020 |
| 32028998 | Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock. | Crit Care | 2020 |
| 30992045 | Broad spectrum vasopressors: a new approach to the initial management of septic shock? | Crit Care | 2019 |
| 32166277 | Synthetic Human Angiotensin II in Pediatric Patients With Vasodilatory Shock: A Report on Two Patients. | Crit Care Explor | 2019 |
| 30768522 | The authors reply. | Crit Care Med | 2019 |
| 30784615 | Therapeutic Opportunities for Hepcidin in Acute Care Medicine. | Crit Care Clin | 2019 |
| 31161442 | Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial. | Ann Intensive Care | 2019 |
| 29509568 | Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II. | Crit Care Med | 2018 |
| 30368243 | Angiotensin converting enzyme defects in shock: implications for future therapy. | Crit Care | 2018 |
| 28528561 | Angiotensin II for the Treatment of Vasodilatory Shock. | N Engl J Med | 2017 |
| 28215131 | Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3): protocol for a phase III, double-blind, randomised controlled trial. | Crit Care Resusc | 2017 |
| 26704388 | Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells. | Biochim Biophys Acta | 2016 |
| 24743136 | End-tidal carbon monoxide and hemolysis. | J Perinatol | 2014 |
| 27536450 | Pharmacodynamic evaluation of intragastric pH and implications for famotidine dosing in the prophylaxis of non-steroidal anti-inflammatory drug induced gastropathy-a proof of concept analysis. | J Drug Assess | 2014 |
| 23616075 | Bridging the gap between basic and applied biology: towards preclinical translation. | Dis Model Mech | 2013 |
| 23828643 | Linking academia and industry to bring drugs to the clinic: an interview with George Tidmarsh. | Dis Model Mech | 2013 |
| 22402354 | The generic drug shortage. | Clin Adv Hematol Oncol | 2012 |
| 19687729 | A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma. | Am J Clin Oncol | 2010 |
| 18337683 | Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinoma: implications for its utilization in assessing malignant lesions. | Q J Nucl Med Mol Imaging | 2009 |
| 19188061 | A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. | Eur J Cancer | 2009 |
| 17661038 | A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma. | Cancer Chemother Pharmacol | 2008 |
| 17786181 | A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo. | Neoplasia | 2007 |
| 17538184 | Liposomal doxorubicin and the accelerated approval process. | J Clin Oncol | 2007 |
| 16110029 | Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. | J Clin Oncol | 2005 |
| 14729604 | 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. | Cancer Res | 2004 |
| 11579112 | Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. | J Clin Oncol | 2001 |
| 10715303 | Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. | J Clin Oncol | 2000 |
| 10942366 | Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. | Blood | 2000 |
| 8927055 | Identification of a novel bone marrow-derived B-cell progenitor population that coexpresses B220 and Thy-1 and is highly enriched for Abelson leukemia virus targets. | Mol Cell Biol | 1996 |
| 8507864 | In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. | Blood | 1993 |
| 2809203 | The early B lineage antigen BP-1 and the transformation-associated antigen 6C3 are on the same molecule. | J Immunol | 1989 |
| 2577321 | Maturation of hematolymphoid cells that express Thy-1. | Immunol Ser | 1989 |
| 2474759 | Identification of a novel bone marrow-derived B-cell progenitor population that coexpresses B220 and Thy-1 and is highly enriched for Abelson leukemia virus targets. | Mol Cell Biol | 1989 |
| 2460755 | The in vitro translation product of the murine lambda 5 gene contains a functional signal peptide. | Mol Immunol | 1988 |
| 3263441 | A new lymphocyte-specific gene which encodes a putative Ca2+-binding protein is not expressed in transformed T lymphocyte lines. | J Immunol | 1988 |
| 3257459 | Normal thymic cortical epithelial cells developmentally regulate the expression of a B-lineage transformation-associated antigen. | Immunogenetics | 1988 |
| 3493323 | Expression of the 6C3 antigen on murine hematopoietic neoplasms. Association with expression of abl, ras, fes, src, erbB, and Cas NS-1 oncogenes but not with myc. | J Exp Med | 1987 |
| 3493849 | Bone marrow stromal cell lines with lymphopoietic activity express high levels of a pre-B neoplasia-associated molecule. | Cell | 1987 |
| 3489809 | Expression of a monoclonal antibody-defined, B-lineage transformation antigen specifically identifies Abelson-diseased animals. Genetically determined resistance to Abelson murine leukemia virus acts before induction of gp160(6C3). | J Exp Med | 1986 |
| 2997360 | Transformed lymphocytes from Abelson-diseased mice express levels of a B lineage transformation-associated antigen elevated from that found on normal lymphocytes. | J Exp Med | 1985 |
| 6222161 | Rapid release of iron from ferritin by siderophores. | J Inorg Biochem | 1983 |